Publications by authors named "Sue Downing"
Objective: To evaluate safety and efficacy of LDI-100, a preparation containing human chorionic gonadotropin (hCG) and bacillus Calmette-Guerin (BCG), in the treatment of dogs with mast cell tumors and to compare results with those from a control group receiving single-agent vinblastine.
Animals: 95 dogs with measurable grade II or III mast cell tumors.
Procedures: Dogs were randomized to receive either LDI-100 (1.
Article Synopsis
- The study aimed to test the safety and effectiveness of a new oral cancer drug, SU11654, in dogs with naturally occurring tumors, targeting various receptor tyrosine kinases (RTKs) associated with tumor growth.
- In a Phase I trial, 57 dogs with different cancers that did not respond to standard treatments received increasing doses of SU11654, and their responses were monitored for effects on tumors and potential side effects.
- Results showed that 28% of dogs had measurable improvements, including complete responses in some, while 54% showed meaningful disease stability, suggesting that this approach could also be viable for treating cancers in humans due to similarities in tumor biology.
Article Synopsis
- - The study aimed to assess the occurrence of internal tandem duplications (ITDs) in c-kit genes in mast cell tumors (MCTs) in dogs and their potential impact on prognosis.
- - Out of 157 dog tumor samples, ITDs were found in 33% of cases, with a higher prevalence in grade-II and grade-III tumors compared to grade-I tumors, indicating a possible correlation between ITDs and tumor severity.
- - The findings suggest that the frequent presence of c-kit mutations in dog MCTs supports their use as a model for testing new cancer treatments, such as small-molecule kinase inhibitors like imatinib mesylate.